Bionano Genomics, Inc.
| Security | BNGO / Bionano Genomics, Inc. |
| Insider | Alka Chaubey |
This page shows the track record and history of Chaubey Alka
insider trades in Bionano Genomics, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company.
It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean
it is illegal for them to make any
trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Alka Chaubey in BNGO / Bionano Genomics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Max |
Price at Max |
Max Profit ($) |
Max Return (%) |
|---|---|---|---|---|---|---|---|
| There are no known unplanned open-market trades for this insider |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Alka Chaubey in BNGO / Bionano Genomics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
|---|---|---|---|---|---|---|---|
| There are no known unplanned open-market trades for this insider |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Transaction History
| File Date |
Trade Date |
Form | Insider | Ticker | Security Title | Code | Direct | Exercise Price |
Unit Price |
Units Changed |
Value Changed (1K) |
Remaining Options |
Remaining Shares |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-12 | 2025-09-11 | 4 | Chaubey Alka | BNGO | Common Stock | D | 4.0600 | -51 | -0 | 662 | ||||
| 2025-06-03 | 2025-06-03 | 4 | Chaubey Alka | BNGO | Common Stock | D | 3.6900 | -24 | -0 | 713 | ||||
| 2025-02-19 | 2025-02-15 | 4 | Chaubey Alka | BNGO | Common Stock | D | 5.7300 | -18 | -0 | 737 | ||||
| 2024-09-13 | 2024-09-11 | 4 | Chaubey Alka | BNGO | Common Stock | D | 0.4800 | -3,075 | -1 | 45,323 | ||||
| 2024-06-05 | 2024-06-03 | 4 | Chaubey Alka | BNGO | Common Stock | D | 16,000 | 48,245 | ||||||
| 2024-03-05 | 2024-02-15 | 4 | Chaubey Alka | BNGO | Common Stock | D | 1.2700 | -1,081 | -1 | 31,487 | ||||
| 2023-09-20 | 2023-09-18 | 4 | Chaubey Alka | BNGO | Common Stock | D | 20,000 | 144,794 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Chaubey Alka | BNGO | Common Stock | D | 120,000 | 124,794 | ||||||
| 2022-02-15 | 2022-02-15 | 4 | Chaubey Alka | BNGO | Stock Option (Right to Buy) | D | 2.18 | 550,000 | 550,000 | |||||
| 2021-04-02 | 2021-04-01 | 4 | Chaubey Alka | BNGO | Stock Option (Right to Buy) | D | 7.83 | 275,000 | 275,000 | |||||
| 2020-09-03 | 3 | Chaubey Alka | BNGO | No securities are beneficially owned | D | 0 | ||||||||
| 2020-09-03 | 2020-09-01 | 4 | Chaubey Alka | BNGO | Stock Option (Right to Buy) | D | 0.56 | 300,000 | 300,000 | |||||
| 2020-09-03 | 2020-09-01 | 4/A | Chaubey Alka | BNGO | Stock Option (Right to Buy) | D | 0.56 | 300,000 | 300,000 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
